William Blair downgraded Enfusion (ENFN) to Market Perform from Outperform without a price target after the company announced an agreement to be acquired by Clearwater Analytics (CWAN) for $11.25 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENFN:
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Enfusion downgraded to Hold from Buy at Stifel
- Enfusion to Merge with Clearwater Analytics Holdings
- Clearwater Analytics to acquire Enfusion for $11.25 per share in cash, stock
- Enfusion price target raised to $11.50 from $10 at Piper Sandler